» Articles » PMID: 18836471

The Tumor Microenvironment and Its Role in Promoting Tumor Growth

Overview
Journal Oncogene
Date 2008 Oct 7
PMID 18836471
Citations 1106
Authors
Affiliations
Soon will be listed here.
Abstract

The tumor microenvironment is created by the tumor and dominated by tumor-induced interactions. Although various immune effector cells are recruited to the tumor site, their anti-tumor functions are downregulated, largely in response to tumor-derived signals. Infiltrates of inflammatory cells present in human tumors are chronic in nature and are enriched in regulatory T cells (T(reg)) as well as myeloid suppressor cells (MSC). Immune cells in the tumor microenvironment not only fail to exercise antitumor effector functions, but they are co-opted to promote tumor growth. Sustained activation of the NF-kappaB pathway in the tumor milieu represents one mechanism that appears to favor tumor survival and drive abortive activation of immune cells. The result is tumor escape from the host immune system. Tumor escape is accomplished through the activation of one or several molecular mechanisms that lead to inhibition of immune cell functions or to apoptosis of anti-tumor effector cells. The ability to block tumor escape depends on a better understanding of cellular and molecular pathways operating in the tumor microenvironment. Novel therapeutic strategies that emerge are designed to change the pro-tumor microenvironment to one favoring acute responses and potent anti-tumor activity.

Citing Articles

Exosome-based miRNA delivery: Transforming cancer treatment with mesenchymal stem cells.

Balaraman A, Babu M, Afzal M, Sanghvi G, M M R, Gupta S Regen Ther. 2025; 28:558-572.

PMID: 40034540 PMC: 11872554. DOI: 10.1016/j.reth.2025.01.019.


Metal-organic framework-based smart stimuli-responsive drug delivery systems for cancer therapy: advances, challenges, and future perspectives.

Guo Z, Xiao Y, Wu W, Zhe M, Yu P, Shakya S J Nanobiotechnology. 2025; 23(1):157.

PMID: 40022098 PMC: 11871784. DOI: 10.1186/s12951-025-03252-x.


Relationship of Desmoplastic Reaction and Tumour Budding in Primary and Lung Metastatic Lesions of Colorectal Cancer and Their Prognostic Significance.

Kobayashi T, Ishida M, Matsui H, Uehara H, I S, Yamada N Cancers (Basel). 2025; 17(4).

PMID: 40002175 PMC: 11852406. DOI: 10.3390/cancers17040583.


Development of an ALK-positive Non-Small-Cell Lung Cancer in Vitro Tumor 3D Culture Model for Therapeutic Screening.

Berry M, Bland A, Major G, Ashton J J Histochem Cytochem. 2025; 73(1-2):63-79.

PMID: 39991927 PMC: 11851580. DOI: 10.1369/00221554251318435.


Multifaceted roles of ninjurin1 in immunity, cell death, and disease.

Zhu L, Xu Y Front Immunol. 2025; 16:1519519.

PMID: 39958360 PMC: 11825492. DOI: 10.3389/fimmu.2025.1519519.


References
1.
Aller M, Arias J, Nava M, Arias J . Posttraumatic inflammation is a complex response based on the pathological expression of the nervous, immune, and endocrine functional systems. Exp Biol Med (Maywood). 2004; 229(2):170-81. DOI: 10.1177/153537020422900206. View

2.
Ostrand-Rosenberg S . Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr Opin Immunol. 2004; 16(2):143-50. DOI: 10.1016/j.coi.2004.01.003. View

3.
Lee J, Lee K, Kim D, Heo D . Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol. 2004; 172(12):7335-40. DOI: 10.4049/jimmunol.172.12.7335. View

4.
Greten F, Eckmann L, Greten T, Park J, Li Z, Egan L . IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004; 118(3):285-96. DOI: 10.1016/j.cell.2004.07.013. View

5.
Curiel T, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P . Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004; 10(9):942-9. DOI: 10.1038/nm1093. View